# US 2022/0031718 A1 · Glucose infusion solution composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031718 A1
- Document ID: US20220031718A1
- Status: Published application
- Kind: A1
- Application number: 17/506,227
- Filed: 2021-10-20
- Published: 2022-02-03
- Earliest claimed: 2017-03-15
- Inventors: Geon Moo Lee; In Seong Lee; Jun Seong Lee; Mi Boon Chung; Jin Kyu Song
- Web page: https://patentgrep.com/patent/US20220031718A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An infusion solution composition having enhanced stability is disclosed.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

A method for promoting health, comprising:
administering to a subject an intravenous injection comprising glucose, galactose, mannose, L-fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine, and N-acetylneuraminic acid.

### Claim 8 (depends on 7)

The method of claim 7, wherein the intravenous injection comprising a stabilizer.

### Claim 9 (depends on 8)

The method of claim 8, wherein the stabilizer is an amino acid.

### Claim 10 (depends on 9)

The method of claim 9, wherein the amino acid is one or more selected from the group consisting of methionine, phenylalanine, histidine and aspartic acid.

### Claim 11 (depends on 8)

The method of claim 8, wherein the stabilizer is aspartic acid.

### Claim 12 (depends on 7)

The method of claim 7, wherein the intravenous injection comprises methionine, phenylalanine, histidine and aspartic acid as stabilizers.
